Trial ID or NCT#

NCT02169037

Status

NOT RECRUITING

Purpose

This is a prospective randomized study to assess the safety and efficacy of FIRM (Focal Impulse and Rotor Modulation)-guided ablation for the treatment of symptomatic atrial fibrillation (AF). The study hypothesis is that the efficacy of AF elimination at 1 year will be higher by ablating patient-specific AF-sustaining rotors and focal sources by Focal Impulse and Rotor Modulation (FIRM) compared to conventional ablation alone (wide-area PV isolation).

Official Title

Substrate Ablation (Focal Impulse and Rotor Modulation) Compared to Pulmonary Vein Isolation to Eliminate Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial

Eligibility Criteria

Ages Eligible for Study: Older than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Paul J. Wang, MD
Cardiac electrophysiologist
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Bioengineering at the Stanford University Medical Center
Sanjiv Narayan
Cardiac electrophysiologist
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Sanjiv M Narayan, MD, PhD
(650) 723-6393